COMMUNIQUÉ DE PRESSE

par AFYREN (EPA:ALAFY)

Inside Information / News release on accounts, results

image                                                                                           PRESS RELEASE

image 

AFYREN announces its       2024 half-year  financial results  

AFYREN NEOXY: first products commercialized but adjustments in operations needed to reach continuous production  o Ambition to reach continuous production by end 2024 is maintained, subject to adjustments to the separation-purification stage

o First tons of biobased acids and fertilizers commercialized to customers

•     Further development of partnerships and commercial pipeline to prepare for the future 

•     First sustainability report published and good execution of the ESG roadmap

A solid financial base, supporting the start-up of AFYREN NEOXY 

•     Stable loss reflecting good control of operating expenses 

•     Cash position of €43 million at 30 June 2024, with cash burn of €6 million, including transitional support for the start-up of AFYREN NEOXY's continuous production

 

 

Clermont-Ferrand/Lyon, September 30, 2024, 07h30 CEST - AFYREN, a greentech company that offers manufacturers natural, low-carbon ingredients produced using unique fermentation technology based on a completely circular model, today announced financial results for the half-year ended June 30, 2024, and approved by the Board of Directors on September 27, 2024. 

Nicolas SORDET, CEO of AFYREN, said: "This summer saw many temperature records fall. Faced with this reality, repeating year after year, AFYREN is proud to offer a concrete response to the challenges of decarbonizing industry. The strategic priority given to the continuous start-up of our AFYREN NEOXY plant should not overshadow the many successes achieved in other areas, whether in R&D, partnerships, our ESG roadmap or the commercial pipeline."

 

             

 

RECENT HIGHLIGHTS

 

AFYREN NEOXY: tangible progress made with the first tons of biobased acids and fertilizer commercialized to customers, while continuous production is envisaged after the adjustments currently being made to the separation-purification stage 

 

Following the on-time delivery of the AFYREN NEOXY plant and its successful industrial commissioning, several quarters of tests and trials were necessary for the teams to master the critical stages of a pioneering process second to none, worldwide.

During this period, the upstream fermentation-concentration process was confirmed. Adjustment work is now focusing on the downstream stages of the process. 

Role

Objective

Status 

Fermentation & Concentration

Enable transformation of feedstock into Acids

Replicating the pilot's performance on an industrial scale

Confirmed 

Concentrate reaction medium

Achieve expected performances 

Confirmed

Separation &

Purification

 

Extract Acids and produce

Fertilizer

Improve the reliability of industrial equipment and process

management

Several long cycles successfully executed 

Reliability work in progress to enable more stable continuous operation

Purification of Acids 

Produce in line with standard market specifications

Largely validated by the production of industrial volumes at the quality required by customers           

Ongoing replacement of a piece of equipment damaged by a corrosion incident

These recent advances have enabled: 

•     the production and commercialization of over a hundred tons of fertilizer since April 2024; 

•     the production of several dozen tons of acids and commercialization to three customers, meeting the quality standards of the human food, cosmetics, and life sciences markets.

AFYREN NEOXY will record its first acids sales in the second half of 2024.

Adjustment in operations required to achieve continuous production. These relate to the separationpurification, in particular with the ongoing replacement of a piece of equipment damaged by a corrosion incident, with the ambition to resume full production cycles at the end of November 2024. Achieving the objective of continuous production by the end of 2024 therefore depends on replacing this equipment without delay and more generally, the ongoing improvement in the reliability of separation-purification. 

The objective of reaching break-even[1] of the plant in the course of 2025 is confirmed.

AFYREN NEOXY: a financing plan for the start-up of operations currently being structured

Today, as anticipated, additional financing requirements, including operating costs related to the startup as well as the necessary investments, are covered for now by a shareholder loan from AFYREN to its subsidiary AFYREN NEOXY. To date, this financing facility amounts to €7.8 million. 

A more comprehensive financing package, including debt financing, is currently being structured. 

image 

AFYREN would participate in this plan as a 51% shareholder in AFYREN NEOXY by mobilizing part of its available cash. It would cover start-up delays and the ramp-up period, right through to financial equilibrium.  

Strategic partnerships and commercial progresses 

 

In parallel with the launch of AFYREN NEOXY, a strategic priority for the Group, AFYREN is continuing to make progress on securing raw materials and commercial outlets for its products. 

In the first half of 2024 AFYREN and SUEZ announced that they would be continuing their collaboration on a new way of recovering biowaste. The aim of this collaboration is to use this waste from SUEZ's collection and treatment activities in the AFYREN process to manufacture molecules that can be used to replace petroleum-based molecules. This initiative opens up an attractive recycling option and a concrete, circular solution to the challenges of decarbonization. It marks a significant step forward in the collaboration between the two companies, initiated in 2020 as part of the AFTER-BIOCHEM consortium. 

In Asia, AFYREN is progressing with the structuring of its commercial activities, within the framework of the planned partnership with Mitr Phol, a leading Thai group in the production of cane sugar and its derivatives, via the creation of AFYREN SERVICES (THAILAND) CO. LTD, a wholly owned subsidiary of AFYREN.

More recently, AFYREN announced the signature of a new multi-year commercial contract with a USbased manufacturer of nutraceutical products, a high-value and fast-growing market. As part of the contract, AFYREN will supply the customer with its biobased acids, produced using its unique natural fermentation process and used as preservatives or flavorings for food supplements. Initially based on limited volumes, this contract may evolve towards larger quantities.

Tangible progress on the ESG[2] roadmap   

 

Integral to AFYREN's value proposition and supported by ambitious corporate governance, ESG is at the heart of AFYREN's strategy. 

Recent achievements include: 

•       Signing of the global Responsible Care® charter attesting to the commitment of all AFYREN sites; 

•       Success of the second HR survey (AFYREN Global People Survey), with 98% participation;

•       Improvement of the Gaia non-financial rating: in March 2024, AFYREN recorded a further improvement in its EthiFinance non-financial rating to 83/100 (Platinum Level), highlighting a level of ESG maturity superior to that of comparable companies[3]

•       Publication of AFYREN's first sustainability report, voluntarily drawn up in the spirit of the ESRS (Environmental, Social, and Governance Reporting Standards). This document is available for consultation and download in a dedicated section of the company's website. 

A SOLID FINANCIAL BASE 

A stable loss thanks to disciplined cost management 

Simplified P&L (in thousands of euros)

06/2024

06/2023

Var.

Revenue

1,364

1,956

-30%

licensing and development of industrial know-how

709

708

-

other services provided 

Operating loss

Net financial result

Share in loss of equity-accounted company (net of tax)

656

1,247

(3,097) 503

(2,529)

-47%

+16%

+94%

+7%

(3,590)

978

(2,710)

Net loss

(5,322)

(5,123)

+4%

The Company's revenues amounted to €1.36 million in the first half of 2024, a 30% decline compared with €1.96 million in the first half of 2023, in line with a reduced scope of services provided to its subsidiary AFYREN NEOXY, given the increased activity of local teams.

image 

Revenues are essentially made up of: 

•     income from patent and know-how licenses granted to AFYREN NEOXY since December 2018 for a total of €0.7 million in the first half of 2024 (€1.4 million on an annual basis) unchanged from the first half of 2023; 

•     various contracts for provision and other service provision (technical, commercial, administrative, etc.) signed with AFYREN NEOXY for a total of €0.7 million in the first half of 2024, down due to the reduction in administrative services linked to specific projects and, more generally, local teams taking up an increased workload. 

Net operating expenses[4] amounted to €5.0 million in the first half of 2024, down slightly from €5.1 million in the first half of 2023. 

These expenses include: 

•     purchases and external expenses, up €0.1 million, including expenses related to the development of the Group's next plants;

•     personnel expenses, down €0.2 million, due to lower costs for share-based payments. The average number of full-time equivalents (FTEs) was 46, compared with 40 at 30 June 2023 (excluding AFYREN NEOXY). 

In addition, research and development spending recognised as expenses amounted to €0.9 million in the first half of 2024, stable compared with the same period in 2023. 

Current operating income came to €(3.6) million, with lower expenses partially offsetting lower revenues.

Net financial income was positive in the first half of 2024: financial income from cash investments totalled

€1.0 million in the first half of 2024, compared with €0.7 million in the first half of 2023. Financial expenses were lower in 2024 than in the first half of 2023, which included interest linked to IFRS restatements (on convertible bonds and licence agreements).

AFYREN NEOXY's share of net income was €(2.7) million in the first half of 2024, compared with €(2.5) million in the first half of 2023. This result is mainly related to the plant's operating expenses, with no meaningful revenues. 

Group net income was €(5.3) million at the end of June 2024, compared with €(5.1) million at the end of June 2023, reflecting good cost control pending the positive contribution from production at the AFYREN NEOXY plant.

A solid cash position of €43 million thanks to limited cash consumption

Simplified balance sheet (in thousands of euros)

06/2024

12/2023

Non-current financial assets

16,671

19,479

of which equity-accounted securities

11,475

14,185

Current assets

47,246

50,948

of which cash and cash equivalents 

Total assets 

Equity

43,402

49,559

70,427

61,799

63,917

56,734

Non-current provisions 

3,477

4,213

of which loans and financial debts  Current liabilities 

2,390

3,176

4,414

3,706

of which loans and financial debts 

1,585

1,611

Total liabilities

63,917

70,427

At 30 June 2024, Group has a cash position of €43.4 million. Cash outflows totaled €6.2 million in the first six months of 2024, of which €2.5 million related to short-term financing of the subsidiary AFYREN NEOXY by means of a shareholder loan, and €0.7 million related to debt repayments.

image 

At the end of June 2024, AFYREN had a solid balance sheet and shareholders' equity of €56.7 million, with the decrease compared with the end of 2023 attributable to the net loss for the period. Total financial debt was limited to €4.0 million[5] at the end of June 2024, compared with €4.8 million at the end of 2023, with the decrease mainly due to the normal repayment of debt.

 

OUTLOOK AND FINANCIAL OBJECTIVES 

 

As of the date of this press release, AFYREN aims at starting up continuous production at AFYREN NEOXY, the first industrial-scale production unit using its technology. 

Experience feedback from AFYREN NEOXY is a prerequisite for launching more advanced engineering studies on two projects: a plant in Thailand targeting the Asian market and the extension of the French plant to meet demand in Europe. 

AFYREN aims for:

•               three production units with an installed capacity of around 70,000 tons of acids in 2028, including at least two in continuous production (including the existing AFYREN NEOXY plant). These three units will also produce a high added-value fertilizer to ensure the circularity of the model; With all three units running at full capacity, AFYREN aims for: 

•               cumulated production revenue of more than €150 million; 

•               a target recurring EBITDA margin at Group level of around 30%[6]

  

2024 HALF-YEAR FINANCIAL REPORT AVAILABILITY

 

The Company will make its 2024 half-year financial report in French available to the public today. An English version will follow shortly. 

             

image 

About AFYREN 

AFYREN is a French greentech company launched in 2012 to meet the challenge of decarbonizing industrial supplies. Its natural, innovative and proprietary fermentation technology valorizes local biomass from non-food agricultural co-products, replacing petro-sourced ingredients usually used in many product formulations.  AFYREN's 100% biobased, low-carbon and sustainable solutions can meet decarbonization challenges in a wide variety of strategic sectors: human and animal nutrition, flavors and fragrances, life sciences and materials, and lubricants and technical fluids. AFYREN's plug-andplay, circular technology combines sustainability and competitiveness, with no need for manufacturers to change their processes.  

The Group's first French plant, AFYREN NEOXY, a joint venture with Bpifrance's SPI fund, is located in the Grand-Est region of France, in Saint Avold, serving mainly the European market. 

AFYREN is also pursuing a project in Thailand with a world leader in the sugar industry, and is developing its presence in the Americas, following up on distribution agreements it has already signed.

At the end of 2023, the AFYREN Group employed about 120 people in Lyon, Clermont-Ferrand and Carling Saint-Avold. The company invests 20% of its annual budget in R&D to further develop its sustainable solutions.

AFYREN has been listed on the Euronext Growth® exchange in Paris since 2021 (ISIN code:


FR0014005AC9, mnemonic: ALAFY). 

Find out more: afyren.com

image 

 

Contacts

AFYREN                                                         NewCap

Director for ESG, Communications           Investor Relations   and Public Affairs        Théo Martin / Mathilde Bohin Caroline Petigny                Tel: 01 44 71 94 94 caroline.petigny@afyren.com        afyren@newcap.eu

 

Investor Relations  Mark Reinhard

investisseurs@afyren.com

 

           

NewCap Media Relations  

Nicolas Mérigeau / Gaëlle Fromaigeat Tel: 01 44 71 94 98 afyren@newcap.eu

International Media relations

Bogert-Magnier Communications

James Connell +33 6 2152 1755 jim@bogert-magnier.com


Appendix

 

1. Income statement  

 

(in thousands of euros)                                                                          

           

           Revenue               

06/2024

 

1 364 

Other income                                                                                               

242 

Purchases and external expenses                                                          

(1 675) 

Payroll costs                                                                                                

(3 029) 

Depreciation of fixed assets and rights of use                                       

(405) 

Other expenses                                                                                          

(88) 

Current operating income                                                                

 

(3 590) 

Non-current operating income                                                                  

 - 

Operating income                                                                               

 

(3 590) 

Financial income                                                                                         

1 051 

Financial expenses                                                                                    

(73) 

Net financial income                                                                          

 

978 

Share in income of equity-accounted company (net of tax)                

(2 710) 

Income before tax                                                                               

 

(5 322) 

Income tax                                                                                                   

Net income for the year                                                                    

 

(5 322) 

Earnings per share                                                                               

Basic earnings per share (in euros)                                                        

(0,20) 

Diluted earnings per share (in euros)                                                      

(0,20) 

imageimage                                                                                                                                                                                 06/2023 

                 

1    956

                                                                                                                                                                                                 226

                                                                                                                                                                                           (1 538)

                (3 249)   (406)

                                                                                                                                                                                                 (86)

 image

                                                                                                                                                                                                       -

 image

                                                                                                                                                                                                 746

                                                                                                                                                                                               (243)

                                                                                                                                                                                                 503

2    529)

 image

                                                                                                                                                                                                       -

 image

                                                                                                                                                                                              (0,20)

                                                                                                                                                                                              (0,20)

2. Balance sheet

 

             

(in thousands of euros)                                                                               

                 

                 

Intangible assets                                                                                              

 

06/2024 

 

  3 146 

Property, plant and equipment                                                                      

  285 

Rights of use                                                                                                    

  328 

Equity-accounted securities                                                                           

  11 475 

Non-current financial assets                                                                          

  1 437 

Non-current assets                                                                                     

                 

  16 671 

Trade receivables                                                                                            

  352 

Current financial assets                                                                                  

  100 

Other current assets                                                                                       

  3 392 

Cash and cash equivalents                                                                            

  43 402 

Current assets                                                                                              

                                 

  47 246 

Total assets                                                                                                   

  63 917 

                 

Share capital                                                                                                    

  522 

Issue premiums                                                                                               

  85 391 

Reserves                                                                                                           

(9 815) 

Retained earnings                                                                                           

(14 042) 

Net income for the year                                                                                  

(5 322) 

Equity attributable to the owners of the Company                  

  56 734 

Non-current borrowings and financial liabilities                                          

  2 269 

Non-current lease liabilities                                                                            

  121 

Defined benefit liabilities                                                                                

  61 

Non-current provisions                                                                                   

  14 

Non-current deferred income (customer contract liabilities)                     

  0 

Non-current deferred income (grant)                                                            

  1 012 

Non-current liabilities                                                                                 

                 

  3 477 

Current borrowings and financial liabilities                                                  

  1 391 

Current lease liabilities                                                                                   

  193 

Trade payables                                                                                                

  282 

Current deferred income (customer contract liabilities)                            

  637 

Other current liabilities                                                                                    

  1 202 

Current liabilities                                                                                         

                 

  3 706 

Total liabilities                                                                                              

  7 183 

 

Total equity and liabilities                                                                         

  63 917 

imageimageimageimageimage                                                                                                                                                                                  12/2023 

                 

image 

                  3 333      338 

                                                                                                                                                                                                 441 

                                                                                                                                                                                            14 185 

                                                                                                                                                                                              1 182 

                 19 479                   

                  466         99 

                                                                                                                                                                                                 824 

49  559 

50  948 

 image

                                                                                                                                                                                                 520 

                85 264                  (4 679) 

                                                                                                                                                                                            (9 720) 

                                                                                                                                                                                            (9 586) 

                 61 799                   

                                                                                                                                                                                              2 952 

                  224         61 

                  14           0 

                                                                                                                                                                                                 962 

                 4 213     

                                                                                                                                                                                              1 402 

                208         388 

                 

3. Cash flow statement (simplified)

 

(in thousands of euros)

 

Net income for the year

 06/2024 

(5 322)

Total elimination of expenses and income with no cash impact 

2 574

Total cash flow

(2 748)

Total changes in working capital

(635)

Net cash from operating activities

(3 383)

Acquisition of PPE and intangible assets, net of disposals

(52)  

Capitalised development expenses

(19)  

Investment grants (incl. CIR offsetting capitalised expenses)

49

Subscription to AFYREN NEOXY capital increase

-  

Current account contribution to AFYREN NEOXY

(2 500)

Interest received

  838  

Net variation in non-current financial assets

(50)  

Variation in current financial assets (liquidity contract)

(1)  

Net cash used in investing activities

(1 735)

Capital increase

  129 

Purchase / sales of treasury share

(306) 

Proceeds from new borrowings and financial liabilities

Repayment of borrowings and financial liabilities

(702) 

Repayment of convertible bonds

Payment of lease liabilities

(110) 

Interest paid on borrowings and financial liabilities

(38) 

Interest paid on bonds

Interest paid on lease liabilities

(10)

Net cash used in financing activities

(1 039)

 

 

Net change in cash and cash equivalents

(6 157)

Cash and cash equivalents as of January 1st 

49 559

Cash and cash equivalents as of Dec 31

43 402

imageimage                                                                                                                                                                               06/2023

            (1 501)              (400)  

image                                                                                                                                                                                      (3 557)

                                                                                                                                                                                             93 

                                                                                                                                                                                         (202) 

                                                                                                                                                                                        1 001 

                                                                                                                                                                                         (818) 

            (3 567)              (110) 

                                                                                                                                                                                          (27) 



[1] Current EBITDA from production: corresponding to current operating income adjusted for depreciation, amortization and net impairment of property, plant and equipment and intangible assets and the royalties for the remuneration of a technology licence granted by AFYREN.

[2] Environmental, social and governance criteria  

[3] In terms of employee numbers and sector

[4] Net of other income, mainly operating grants including in particular the research tax credit

[5] Including rental liabilities, which represent 121 thousand euros at the end of June 2024 for the non-current portion and 193 thousand euros for the current portion

[6] Current EBITDA margin is defined at Company level.

Voir toutes les actualités de AFYREN